

Interview Summary	Application No.	Applicant(s)	
	09/807,201	SALCEDA ET AL.	
	Examiner	Art Unit	
	MINH-TAM DAVIS	1642	

All participants (applicant, applicant's representative, PTO personnel):

- (1) MINH-TAM DAVIS. (3) Herve Recipon.
 (2) Kathleen Tyrrell. (4) _____.

Date of Interview: 17 December 2003.

Type: a) ☒ Telephonic b) ☐ Video Conference
 c) ☐ Personal [copy given to: 1) ☒ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.
 If Yes, brief description: _____.

Claim(s) discussed: all pending claims.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

 Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Discussion of the following issues 1) restriction of a method of diagnosing prostate cancer comprising determining the level of mRNA of the polynucleotide of SEQ ID NO:7 or 8, from of a method of diagnosing prostate cancer comprising determining the protein level of the polypeptide encoded by the polynucleotide of SEQ ID NO:7 or 8, 2)112, first scope and written description rejection of the language "level" of SEQ ID NO:7 or 8, and detection of prostate cancer in any tissue, cell or bodily fluid..